Break it Down: Tryptamine raises $6.1m to fast-track world-first binge eating disorder trial

Stockhead’s Break it Down brings you today’s leading market news in under 90 seconds.

In this episode, host Tylah Tully looks at Tryptamine Therapeutics (ASX:TYP) latest capital raise to accelerate its TRP-8803 clinical program. 

The company has raised $6.1 million via a placement of just over 174 million shares, receiving strong backing from both institutional investors and company insiders. 

Watch the video to hear the details.

While Tryptamine Therapeutics is a Stockhead advertiser, it did not sponsor this content.